, Tracking Stock Market Picks
Enter Symbol:
Cardiome Pharma Corporation (CRME) [hlAlert]

down 77.83 %

Cardiome Pharma Corporation (CRME) rated Buy with price target $10.75 by UBS

Posted on: Wednesday,  Jun 23, 2010  10:25 AM ET by UBS

UBS rated Buy Cardiome Pharma Corporation (NASDAQ: CRME) on 06/23/2010, when the stock price was $39.75. Since
then, Cardiome Pharma Corporation has lost 77.84% as of 08/27/2015's recent price of $8.81.
If you would have followed this UBS's recommendation on CRME, you would have lost 77.83% of your investment in 1891 days.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/23/2010 10:25 AM Buy
39.75 53.75
as of 12/31/2010
1 Week up  12.54 %
1 Month up  35.61 %
3 Months up  7.37 %
1 YTD down  -17.61 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy